News for Alterity Therapeutics Limited (ATHE)

”“ Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track dise

Alterity Therapeutics (ATHE) introduces the MSA Atrophy Index, a novel tool for assessing brain atrophy in Multiple System Atrophy. The MSA-AI effective

Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidance was raised. Other gainers and losers noted.

MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, ATHE) (”œAlterity” or ”œthe Company”), a bio

Alterity Therapeutics (ATHE) will hold a Fireside Chat to update on its ATH434 development program. The event is scheduled for June 25, 2025 (Australia)

”“ ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints ”“ ”“ MSA Atrophy Index (MSAai) enhances MSA diagnosis and

ATH434 shows 48% reduction in disease severity at 50mg dose in Phase 2 trial. New MSA Atrophy Index (MSAai) improves diagnosis and monitoring of Multipl

**media[617437]**

â\u0080\u0093 Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA â\u0080\u0093 MELBOURNE, Australia and SAN FRANCISCO, May

\n Alterity Therapeutics (ATHE) receives FDA Fast Track designation for ATH434 to treat Multiple System Atrophy (MSA). Positive results from Phase 2 clinic

Alterity Therapeutics (ASX:ATH), dual-listed on both the ASX and the NASDAQ, is the latest Aussie biotech to win an FDA tick with its drug...

Highlights Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust cli

MELBOURNE, Australia and SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, ATHE) (”œAlterity” or ”œthe Company”), a bi

”“ Clinically Meaningful Efficacy Observed on Multiple Assessments ”“ ”“ Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Region

Alterity Therapeutics Limited (ATHE), Thursday announced the data from ATH434 Phase 2 trial in patients with Multiple System Atrophy or MSA. The findings showed clinically meaningful efficacy across multiple measures.

**media[584926]**

”“ Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders ”“ ”“ Capital raising was strongly supported by domestic and intern

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.18% to 44,795.97 while the NASDAQ fel...

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Thursday. The Dow traded up 0.26% to 44,829.59 while the NASDAQ gain...